Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Insider Acquires $99,600.00 in Stock

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) insider David Young purchased 124,500 shares of the business’s stock in a transaction on Monday, January 27th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $99,600.00. Following the purchase, the insider now owns 205,405 shares of the company’s stock, valued at $164,324. This trade represents a 153.88 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Processa Pharmaceuticals Price Performance

NASDAQ PCSA opened at $0.59 on Thursday. Processa Pharmaceuticals, Inc. has a 1-year low of $0.47 and a 1-year high of $3.31. The firm has a market capitalization of $1.94 million, a P/E ratio of -0.17 and a beta of 0.62. The business’s 50-day simple moving average is $0.92 and its 200-day simple moving average is $1.23.

Processa Pharmaceuticals (NASDAQ:PCSA) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.03). On average, equities research analysts expect that Processa Pharmaceuticals, Inc. will post -4.05 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Processa Pharmaceuticals in a research report on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.